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Paraoxonase-1(PON1)isaserumprotein,theactivityofwhichisrelatedtosusceptibilitytocardiovasculardiseaseandintoxication
by organophosphorus (OP) compounds. It may also be involved in innate immunity, and it is a possible lead molecule in the
development of a catalytic bioscavenger of OP pesticides and nerve agents. Human PON1 expressed in E. coli is mostly found
in the insoluble fraction, which motivated the engineering of soluble variants, such as G2E6, with more than 50 mutations from
huPON1. We examined the eﬀect on the solubility, activity, and stability of three sets of mutations designed to solubilize huPON1
with fewer overall changes: deletion of the N-terminal leader, polar mutations in the putative HDL binding site, and selection of
the subset of residues that became more polar in going from huPON1 to G2E6. All three sets of mutations increase the solubility
of huPON1; the HDL-binding mutant has the largest eﬀect on solubility, but it also decreases the activity and stability the most.
Based on the G2E6 polar mutations, we “humanized” an engineered variant of PON1 with high activity against cyclosarin (GF)
and found that it was still very active against GF with much greater similarity to the human sequence.
1.Introduction
Paraoxonase-1 (PON1) is a mammalian serum protein, the
activity of which is related to cardiovascular health and the
toxicology of organophosphorus (OP) compounds [1–3].
PON1 is thought to be synthesized mostly in the liver, and it
isassociatedwithhigh-densitylipoproteins(HDLs)inserum
[4]. The exact function of PON1 is not known, but it is an
eﬃcient hydrolase of lactones and esters and an ineﬃcient
hydrolase of OP compounds, including pesticide metabolites
such as paraoxon (from parathion) and chlorpyrifos oxon,
and nerve agents such as sarin, tabun, and VX [1, 5].
Increased PON1 activity appears to be related to lower levels
of oxidation of low-density lipoprotein (LDL) particles, and
its hydrolytic activity has been suggested to be directed
at oxidized fatty acids and homocysteine thiolactone [6–
8]. Its increased activity has been shown to be related
to decreased atherosclerosis, and it has been implicated
in mechanisms of cholesterol eﬄux [9, 10]. PON1 also
eﬃciently hydrolyzes bacterial lactones involved in quorum
sensing, and it may contribute to innate immunity through
this activity [11]. Although the hydrolysis of OP compounds
is almost certainly a promiscuous activity of the enzyme,
it contributes to the susceptibility to OP intoxication [12],
and PON1 has been suggested as a lead molecule for a
prophylactic or therapeutic bioscavenger of OP toxins [13,
14].HumanPON1,particularlytheR192alloform,isalready
suﬃciently active to protect against chlorpyrifos oxon and
diazoxon exposures without engineering. The turnover of
many other OPs by natural PON1 is not suﬃcient to aﬀord
signiﬁcant protection, but a mammalian chimeric form of
PON1 has recently been engineered for signiﬁcant activity
against some G-agents [15].
As a result of the physiological and toxicological correla-
tions with increased PON1 activity, there is great motivation
todevelopPON1asatherapeuticagent.Therearesigniﬁcant2 Journal of Lipids
diﬃculties with this: PON1 has only moderate solubility;
it has three Cys residues including two forming a disulﬁde
b o n d ,a n di ti sg l y c o s y l a t e d[ 16]. Human PON1 (huPON1)
is very diﬃcult to produce in soluble, folded form in E.
coli. Large-scale fermentation has been used to produce
soluble huPON1 successfully in E. coli, but in poor yields
forpharmaceuticalproduction [14].Thismotivated Aharoni
and colleagues to generate a chimeric mammalian PON1
by DNA shuﬄing of mouse, rat, rabbit, and human PON1
isoforms, resulting in a variant called G2E6 that could be
expressed when fused to the C-terminus of thioredoxin in
good yields in the soluble fraction of E. coli (Figure 1)[ 17].
The crystal structure of G2E6 was solved, revealing it to be
a six-bladed β-propeller protein bound to two Ca2+ ions,
one of which appears to play a more structural role and one
of which is located in what is presumed to be the active-
site pocket [16]. A further generation of DNA shuﬄing and
selection yielded G3C9 PON1, which can be expressed in
signiﬁcantamountsinthesolublefractionofE.coliwithouta
fusion partner (although it bears a C-terminal hexahistidine
tag). Both of the proteins have greatest sequence similarity to
the rabbit isoform of PON1, and they diﬀer by 58-59 (G2E6)
and50-51(G3C9)aminoacidsfromhuPON1,dependingon
the polymorph, mostly on the surface and essentially not at
all in the putative active site. (Human PON1 is either Leu
or Met at 55, while rabbit is only known to be Leu at this
position).
The poor solubility of human PON1 is presumably in
part a consequence of its ability to associate with HDL. The
nature of this interaction is not clearly deﬁned. PON1 has
a signal sequence directing it for cellular export, and it is
mutated at the cleavage site for the signal protease, resulting
of retention of the hydrophobic signal peptide [18, 19]. That
peptideisdisorderedinthestructureofG2E6[16].Thereisa
large hydrophobic patch on the surface of PON1 that is near
the N-terminus, suggesting that this is the HDL interaction
surface. The interaction of PON1 with HDL stimulates its
activity towards lactones, and removal of the signal peptide
(residues 1–20) has been shown to abrogate that stimulation,
suggesting that it is critical for proper embedding in the
apoA-I HDL particle [20]. It is not surprising that most of
the diﬀerences between the very insoluble human PON1 and
the more soluble G2E6 and G3C9 are on the surface of the
protein, as this is where changes would be most expected to
aﬀect the solubility of the folded protein.
Despite this intuitive expectation, surprisingly little is
known about how mutations aﬀect the solubility of pro-
teins or how to engineer proteins for greater solubility.
Several studies have reengineered membrane proteins to
render them soluble. Li and coworkers reengineered phos-
pholamban (PLB), a protein that forms a stable helical
homopentamer within the sarcoplasmic reticulum mem-
brane, into a soluble pentameric helical bundle by replac-
ing its lipid-exposed hydrophobic residues with charged
and polar residues [21]. Based on computational design,
Slovic and coworkers rationally engineered a water-soluble
analog of PLB by changing membrane-exposed positions
to polar or charged amino acids, while the putative core
was left unaltered [22]. These constructs were based on
the hypothesis that membrane proteins and water-soluble
proteins share a similar core and it should be possible to
solubilize membrane proteins by mutating only their lipid-
exposed residues. The redesigned PLBs mimic all of the
reportedpropertiesofPLBincludingoligomericstate,helical
structure, and stabilization upon phosphorylation. Based on
thesameapproach,Slovicandcoworkersredesignedawater-
soluble variant of a membrane protein, potassium channel
KcsA, by mutating the lipid-contacting side chains to more
polar groups [23].
We were interested in determining how mutations to
huPON1 would aﬀect its solubility and soluble expression
in E. coli. We hypothesized that three diﬀerent types of
mutations might increase the solubility of human PON1. We
speculated that (a) removal of the hydrophobic N-terminal
leader sequence and (b) mutations of hydrophobic amino
acids in the presumptive HDL binding site to polar residues
would increase the solubility. We also speculated that (c)
the surface residues which were mutated to be more polar
amino acids during the directed evolution of G2E6 PON1
were mostly responsible for the increased solubility. To test
these ideas, we constructed three mutants of human PON1
called ΔN-huPON1, ΔHDL-huPON1, and g2e6p-huPON1
(Figure 1). We also combined some of the mutations to look
for additive eﬀects on solubility.
To test the solubility of these proteins, we exploited
the screen developed by Waldo and colleagues based on
fusion of an analyte protein (“protein of interest” or POI)
to the N-terminus of the “folding reporter” variant of
green ﬂuorescent protein (frGFP) [24]. Brieﬂy, if the POI
folds and is soluble, then the frGFP also folds and its
chromophore develops, resulting in ﬂuorescent cells. If the
POI is insoluble, then the fusion is found in the membrane-
associated fraction and little ﬂuorescence develops. Waldo
and colleagues demonstrated that the amount of cellular
ﬂuorescence is related to the amount of soluble protein.
Consequently, we fused each of the huPON1 variants to the
N-terminus of frGFP and determined the ﬂuorescence level
of the host bacterial cells. We also examined the activity and
stability of the resulting proteins.
We were also interested in the determinants of huPON1
solubility because we wished to use that knowledge to
generate variants of engineered PON1 that had signiﬁcantly
greater activity toward OP agents, but with a surface
sequence signiﬁcantly more like native huPON1. Little is
known about the immunological eﬀects of the adminis-
tration of heterologous variants, but the large number of
mutations on the surface of G2E6 and G3C9 relative to
human PON1 is a cause for concern. In the ﬁeld of antibody-
based therapeutics, human anti-mouse antibody syndrome
is a common eﬀect of the administration of mouse-derived
antibodies, and so variants of mouse antibodies have been
successfully “humanized” by replacing their surface residues
with a human sequence while maintaining the binding
site residues elicited during aﬃnity maturation [25]. We
speculated that we might be able to “humanize” or at least
partially humanize evolved variants of G3C9 PON1 with
high OP activity by reverting the surface back to the human
sequence, except for solubilizing mutations identiﬁed in theJournal of Lipids 3
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Figure 1: Alignment of PON1 variants. All diﬀerences are noted with respect to the human PON1 sequences (Q192/M55 polymorph); the
4E9 sequence and the similar rabbit PON1 sequence are shown in full for reference. Diﬀerences between G3C9 and 4E9 are noted in red in
the 4E9 sequence. -: deletion.
ﬁrst part of this work. We chose to humanize the recently
reported 4E9 variant (Figure 1)[ 15], which has very high
activity against the cyclosarin (GF) analog CMP, using the
same strategy used to generate g2e6p-huPON1. Because the
substrate speciﬁcities of huPON1 and G2E6 PON1 are quite
diﬀerent despite essentially identical active sites, it was not
clear if humanization could yield an active enzyme [5].
Here we show that humanization of 4E9 was successful and
suggests a path forward for improved therapeutics based on
engineered PON1 variants.
2.MaterialsandMethods
2.1. Cloning huPON1 and frGFP Fusions in pET11a. The
frGFP gene was generated in our lab from the genes for4 Journal of Lipids
GFPuv [26] and EGFP [27] by overlap PCR, resulting in
a GFP with mutations F64L S65T F99S M153T V163A.
The frGFP gene was PCR ampliﬁed with primers coding
for a 6×His tag and an AatII site at the 3  end and
an EcoRI site at the 5  end. Wild-type human PON1
(Q192/M55) was PCR ampliﬁed from a mammalian expres-
sion vector, pcDNA3. The oligonucleotide (Sigma Genosys,
The Woodlands, TX) primers 5 -AATAATTATC ATATGGC-
TAA GCTGATTGCG CTCACCC-3  with an NdeI site, and
5 -ATAATGAATT CGCCGCTGCT TCCGCTCTGA AAAT-
ACAGAT TCTCACCGCC GGTACCGAGT TCGCAGTAAA
GAGCTTTGTG AAACAC-3  coding for a KpnI site,
TEV protease (ENLYFQG) site, linker (GSSG) and EcoRI
site, were used for ampliﬁcation. A fusion of huPON1-
(KpnI-)TEV-Linker-(EcoRI-)frGFP (Figure 2)w a sc l o n e d
into a pET11a vector between the NdeI and AatII sites using
a three-piece ligation. For reference, the G2E6 gene was
analogously cloned into this construct (the gene was kindly
provided by Dan Tawﬁk, Weizmann Institute of Science).
The sequence of the fusion construct was conﬁrmed by DNA
sequencing (Genewiz, South Plainﬁeld, NJ).
2.2. Rationally Engineered huPON1 Variants. To generate
ΔHDL-huPON1 (Figures 1 and 3), twelve Glu, Gln, or
Lys mutations were made at hydrophobic residues in
the putative HDL binding site (Y24E, Y185E, F186Q,
L187K, Y190K, L191Q, W194K, L198E, L200Q, W202K,
M289Q, F293E) in the huPON1 construct. All of these
mutations were introduced at once by overlap PCR.
Three pairs of oligonucleotides were used to amplify three
fragments of the huPON1 gene with all 12 mutations.
The three fragments were then subjected to assembly and
ampliﬁcationsimilartotheﬁnalstepsofDNAshuﬄingusing
two terminal primers, 5 -ATAGATATAC ATATGGCGAA
GCTGATTGCA CTCACGCTCT TGGGGATGGG ACTGGC
ACTC TTCAGGAACC ACC-3  and 5 -CTCACCGCCG
GTACCGAGTT CGCAGTAAAG AGCTTTG-3 . These
primers coded for NdeI and KpnI sites. The ampliﬁed
ΔHDL-huPON1 gene was cloned into pET11-huPON1-
TEV-frGFP vector, replacing huPON1 between NdeI and
KpnI, and the construct was conﬁrmed by DNA sequencing.
The g2e6p-huPON1 was engineered by introducing
surface mutations that became more polar in the directed
evolution of G2E6 from huPON1. Fifteen such mutations
(I5T, N19R, Q21K, L31H, N78D, N80D, S81K, P82S, L98S,
G101E, A137S, Q192K, Y197H, N265D, and N309D) and
an N166S compensatory mutation of the Q192K mutation
were introduced into huPON1 by total gene synthesis using
the TBIO method [28]. Thirty primers of 60nt coding
for all 16 point mutations were designed using DNAWorks
[29]. The assembled full-length gene for g2e6p-huPON1 was
ampliﬁed using two terminal primers, 5 -GTTTAACTTT
AAGAAGGAGA TATACATATG GCAAAGCTGA CCGC-
3  and 5 -TGAAAATACA GATTCTCACC GCCGGTACCT
AATTCACAG-3 , and cloned as described for ΔHDL-
huPON1.
To generate the N-terminal deletion (ΔN) constructs,
residues 4 to 17 (LIALTLLGMGLALF) from the leader
sequence of PON1 were deleted by PCR ampliﬁcation of the
frGFP
PON1
TEV
MBP
PON1
TEV
MBP PON1
TEV His6
His6
His6
Figure 2: Schematics of the fusions used in this study. PON1,
paraoxonase-1 variant; TEV, TEV protease site; frGFP, folding
reporter GFP; His6, hexahistidine tag; MBP, maltose-binding pro-
tein.
host genes. The forward primer 5 -AATAATAATC ATATG-
GCAAA GAGGAACCAC CAGTCTTCTT AC-3  was used
forhuPON1andg2e6p-huPON1;5 -AATAATAATC ATATG-
GCGAA AAGGAACCAC CAGTCTTCAG AAC-3  was used
for ΔHDL-huPON1. The reverse primer 5 -AATAATGAAT
TCGCCGCCGC TTCCGCTCTG AAAATACAG ATTCTC-
3  was used for huPON1 and ΔHDL-huPON1, and
5 -AATAATAATG GTACCTAATT CACAGTATAA TGCTT-
TATGG AAAACCG-3  was used for g2e6p-huPON1. These
were cloned as described for ΔHDL-huPON1.
2.3. GFP-Fusion Assay for Solubility. BL21(DE3) cells were
transformed with engineered pET11a-PON1-frGFP fusion
constructs. LB media (100mL) supplemented with ampi-
cillin were inoculated with 2mL of overnight saturated
culture grown from a single colony. The cells were grown
to OD600 ∼0.7 and induced with 0.1mM IPTG. The fusion
proteins were expressed for 4h at 30◦C and the cells were
incubated at 4◦C for 6h before harvesting by centrifugation.
Cell pellets were resuspended in PBS and washed with
PBS twice before the density of the cells was normalized
by adjusting OD600 to 0.1. Whole-cell ﬂuorescence was
measured in a Perkin Elmer LS50B ﬂuorimeter using 480nm
excitation and 509nm emission.
2.4. Cloning into pHMT. Genes for full-length and N-
terminal deletion variants were cloned into the pHMT
vector [30] (kindly provided by Mark Foster, Ohio State
Biochemistry) between the NcoI and PstI sites as a C-
terminal fusion to maltose-binding protein (MBP). The
vector encodes a 6 ×His tag at the N-terminus of MBP, a
linker (EFGSSRVD), and a TEV protease site (ENLYFQG)
between the MBP and fused protein (Figure 2). For the ease
of cloning, the SalI site in the original vector was replaced
with an NcoI site, and a fragment of unrelated DNA was
inserted between NcoI and PstI sites. The huPON1 variant
genes were ampliﬁed with PCR and cloned between the NcoI
and PstI sites.
2.5. Cloning into pET11a with a C-Terminal 6×His Tag. The
MBP fusions of the huPON1 variants were PCR ampliﬁed
from pHMT using a 5  primer that removes the N-terminal
6×His tag and a 3  primer encoding a new C-terminal
6×H i st a g .G e n e sf o rt h ef u s i o n sw i t haT E Vp r o t e a s es i t eJournal of Lipids 5
betweentheMBPandproteinvariants(Figure2)werecloned
into a pET11a vector between the NdeI and XhoI sites.
2.6. Fusion Protein Expression and Puriﬁcation. Origami B
(DE3) E. coli (Novagen, Madison, WI) were transformed
with plasmids encoding the frGFP fusion or MBP fusion
constructs and grown overnight to saturation. The MBP
fusions were also expressed from cells containing the chaper-
one plasmid pKJE7 (encoding DnaK, DnaJ, and GrpE, from
Takara Bioscience). One liter of LB media supplemented
with appropriate antibiotics and 1mMCaCl2 (and 0.1%
arabinose when pKJE7 was used) was inoculated with 20mL
of saturated culture and grown at 37◦Ct oa nO D 600 of
0.8. Cells were induced with 0.1mM IPTG, sometimes after
brief incubation in an ice-water bath, and grown at 16–30◦C
for 4h to overnight. (Material from diﬀerent induction and
growthconditionshadidenticalspeciﬁcactivityforparaoxon
a n di sp r e s u m e dt ob ei d e n t i c a l ) .
All puriﬁcation was carried out at 4◦C unless stated.
Cells harvested by centrifugation at 6,000g for 10min
were resuspended in lysis buﬀer (50mM Tris-HCl, pH 8.0,
50mMNaCl, 1mMCaCl2, with or without 10% glycerol)
supplemented with 1mM DTT and lysed by extrusion
through a needle and sonication. The lysate was incubated
with 0.1% Tergitol NP-10 (Sigma-Aldrich) on a nutator
at 4◦C for 2-3h. After centrifugation at 27,000g for 1h,
cleared lysate was mixed with Ni-NTA agarose resin (Qiagen,
Valencia, CA) and incubated at 4◦C for 3h with gentle
mixing. The slurry was poured into a chromatography
column and the ﬂow-through fraction was discarded. The
resin was typically washed with lysis buﬀer containing 25–
40mM imidazole and eluted with lysis buﬀer containing
150mM imidazole. It was then exchanged into buﬀer with
10% glycerol using dialysis or a PD10 desalting column (GE
Healthcare) and then into buﬀer containing 50% glycerol
by dialysis. The buﬀer used was 50mM Tris-HCl, pH 7.4,
10mMCaCl2 for proteins assayed against paraoxon and
phenyl acetate and 50mM Tris-HCl, pH 8, 50mMNaCl,
1mMCaCl 2, 0.1% Tergitol NP-10, for proteins assayed
against EMP and CMP. The diﬀerence in buﬀers was merely
due to testing at diﬀerent times by diﬀerent researchers.
Protein concentrations were determined by Bradford assay
(Bio-Rad Laboratories, Hercules, CA) and conﬁrmed by
SDS-PAGE. Samples were stored at −20◦C.
Forthermalinactivationstudies(seebelow)thehuPON1
variants were cleaved away from the MBP fusion protein.
After elution from the NiNTA column, proteins were
exchanged into a buﬀer containing 50mM Tris-HCl, pH 7.4,
10mMCaCl2, 5mM DTT using a PD10 desalting column.
Samples were then treated with TEV protease for 4–6h at
room temperature before subjecting them to Ni-NTA resin
binding again. After 4h of binding at 4◦C, resin slurry
was poured into a chromatography column, washed with
lysis buﬀer containing 20mM imidazole, and eluted with
lysis buﬀer containing 150mM imidazole. Protein samples
were exchanged into 50mM Tris-HCl, pH 8.0, 50mM NaCl,
1mMCaCl 2 using a PD10 desalting column. Samples were
further puriﬁed over an anion exchange column (Resource
Q, GE Healthcare) to separate them from any coeluted
proteins. Pure huPON1 and its variants were eluted using
a gradient of from 50mM Tris-HCl pH 8.0, 50mM NaCl,
1mMCaCl 2 to the same buﬀer with 0.5M NaCl over 50mL.
Pooled fractions were tested for aryl esterase activity and
dialyzed overnight into 50mM Tris-HCl, pH 8.0, 10mM
CaCl2, 50% glycerol, before kinetic measurements.
2.7. Construction and Puriﬁcation of Hum-4E9. The human-
ized4E9protein(hum-4E9)wasdesignedbyintroducingthe
4E9 mutations (L69G S111T H115W H134R F222S T332S)
into the g2e6p-huPON1 sequence. Note that two additional
nonpolar-to-polarmutationsweremadecomparedtog2e6p-
huPON1 (A126T V206T) and that Leu was used at human
polymorphic position 55. The amino acid sequence was
reverse-translated to retrieve the gene sequence, which was
codon-optimized for E. coli expression. The gene sequence
was ordered from Genewiz, which provided the gene in a
pUC57 plasmid. Using BamHI, the hum-4E9 was cloned
into pET11a-MBP vector, yielding an MBP-tag at the N-
terminus and a 6×His tag at the C-terminus. The fusion
was puriﬁed as described above. In order to remove the MBP
fusion, the hum-4E9 variant was also cloned into pET32b
using NcoI and XhoI. For comparison, we also puriﬁed 4E9,
as described, from a plasmid kindly provided by Dan Tawﬁk
[15].
2.8. Enzyme Kinetics. Kinetic parameters for the hydrolysis
ofphenylacetateandparaoxonweredeterminedasdescribed
[5]usinganassaybuﬀercontaining50mMTris-HCl,10mM
CaCl2, pH 7.4. Paraoxon (Sigma) was used from 0.06 to
2.6mM, phenyl acetate was used from 0.06 to 3.3mM,
and EMP (3-cyano-4-methyl-2-oxo-2H-chromen-7-yl ethyl
methylphosphonate) and CMP (3-cyano-4-methyl-2-oxo-
2H-chromen-7-ylcyclohexylmethylphosphonate)wereused
from 0.005mM to 0.5mM. The initial rate of formation of
hydrolysis product at 25◦C was monitored by following the
absorbance at 405nm for p-nitrophenolate from paraoxon
(ε = 14,320M−1 cm−1), at 270nm for phenol from phenyl
acetate (ε = 1,310M−1 cm−1), and at 405nm for 7-hydroxy-
4-methyl-3-cyanocoumarin (MeCyC, ε = 37,000M−1 cm−1)
from EMP and CMP, using an Agilent 8453 UV-Vis spec-
trophotometer or a SpectraMax M5 Pro multiwell plate
reader (Molecular Devices, Sunnyvale, CA) and Greiner One
UV Star plates. Stocks of phenyl acetate, paraoxon, EMP,
and CMP were prepared in methanol. Kinetic parameters for
EMP and CMP were determined at 2% constant methanol.
Parameters were derived by ﬁtting a Michaelis-Menten
model of steady-state enzyme kinetics to the data with
KaleidaGraph (Synergy Software, Reading, PA). EMP and
CMP were kindly provided by Yacov Ashani, Weizmann
Institute of Science, and were synthesized in house by the
method of Ashani et al. [31] (S. Muthukrishanan, D. Mata,
TJM and C. Hadad, unpublished).
To test activity against the more toxic SP isomer of CMP,
theprotocolfromGuptaetal.[15]wasfollowedasdescribed.
In short, racemic CMP (0.025mM) in the presence of 3B3
PON1 (provided by Dan Tawﬁk) was incubated in 50mM
Tris-HCl, 10mM CaCl2, pH 7.4 for 30min at 4◦Ct od e p l e t e
the RP-isomer from the reaction. The reaction mixture6 Journal of Lipids
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166S
192K
Phosphate
(a) (b) (c)
Figure 3: PON1 solubilizing mutations. (a) The surface of G2E6 is shown, with hydrophobic amino acids (VGMCILYFW) shown in red.
Residues1–15arenotresolvedintheX-raycrystalstructure,buttheΔN-huPON1variantremovedresidues4–17.(b)Thepositionsmodiﬁed
in the ΔHDL-huPON1 variant are shown in spheres. These residues compose much of the hydrophobic surface patch near the N-terminus
evident in (a). The Ca2+ ions are shown as pink spheres, and a phosphate bound in the presumed active site is shown in orange sticks. (c)
The 59 positions that diﬀer between huPON1 and G2E6 are shown; the positions that were modiﬁed in g2e6p-huPON1 are spheres, and the
other 43 positions are sticks. Position 166, which was modiﬁed because of its proximity of 192, is noted. Rendered from PDB ID: 1V04 with
PyMOL.
(150μL) and 50μL of diluted enzyme were added to a 96-
well plate.
To determine the kinetics of cyclosarin (GF) hydrol-
ysis, racemic cyclosarin was obtained from the US Army
Edgewood Chemical Biological Center (Aberdeen Proving
Ground, MD). Analysis by NMR spectroscopy showed it to
be >95% pure. Stock solutions of GF in saline were prepared
at 2mg mL−1 and stored at −70◦C. Enzyme was incubated
with 0.3125mM GF in 10mM MOPS, 2mM CaCl2 at
room temperature. At speciﬁc time intervals, 100μL aliquots
were removed and inactivated through extraction with an
equal volume of ethyl acetate containing 50μM diisopropyl
ﬂuorophosphate (DFP; internal standard); this extraction
both inactivates the enzyme and prevents racemization of
nonhydrolyzed GF stereoisomers. The organic layer (con-
taining nonhydrolyzed GF) was then removed and analyzed
by gas chromatography/mass spectrometry (GC/MS).
Chiral gas chromatographic analysis of GF was per-
formed using an Agilent 7890 gas chromatograph (Foster
City, CA) ﬁtted with a 20m × 0.25mm internal diameter
ASTEC G-TA column (Astec, Whippany, NJ). Helium was
used as the carrier gas at an average linear velocity of
54.5cms−1. The oven temperature was held initially at 70◦C
for 1min and then ramped from 70 to 160◦Ca tar a t eo f
10◦Cm i n −1. Split injections (50:1) of 1uL volume were
made using an Agilent 7693 autosampler. The injection port
temperature was 210◦C and the split vent delay was set
at 1min. The GC was interfaced to an Agilent 5975 mass
spectrometer (MS) with an electron impact ion source. The
MS operating conditions were as follows: ion source pressure
approximately 1.0 × 10−5 Torr; source temperature, 230◦C;
quadrupole temperature, 150◦C; electron energy, 70eV;
transferlinetemperature,265◦C.TheMSwasoperatedusing
selected ion monitoring. Ion pairs m/z 99 and 67 and m/z
101 and 127 were monitored for GF and DFP, respectively.
A dwell time of 100ms for each ion pair resulted in a scan
rate of 8.26 cycles s−1.R a t ec o n s t a n t s( kapp) for hydrolysis
of racemic GF were derived by using nonlinear regression to
ﬁt hydrolysis progress curves to a single-phase decay model
using Prism 4.03 (GraphPad Software, La Jolla, CA). Relative
stereoisomeric preference was calculated by determining the
r a t i oo ft h er a t e so fh y d r o l y s i so fe a c he n a n t i o m e ro fG F .
2.9. Thermal Inactivation and Residual Activity Determina-
tion. Protein samples were heated for 10min at diﬀerent
temperatures ranging from 25◦Ct o8 0 ◦C. After a brief
incubation on ice and centrifugation in a picofuge at
2,200g for 2min, their activities were determined from
EMP (0.35mM) or phenyl acetate (3.6mM) hydrolysis. The
residual hydrolysis activity from incubation at 20◦C( p h e n y l
acetate) or 25◦C (EMP) was taken as 100%.
3. Results
3.1. Design of Rationally Engineered Variants. Based on what
is known about the leader sequence, the crystal structure
of G2E6, and sequence comparison of G2E6 to huPON1,
we designed three variants of huPON1 to examine their
eﬀects on the solubility of the protein. The ﬁrst variant, ΔN-
huPON1, is a deletion of residues 4–17, which includes most
oftheleadersequence.Theﬁrstresidueresolvedinthecrystal
structure of G2E6 (PDB ID: 1V04 [16]) is Leu16. The ﬁrst
three residues, MAK, are fairly soluble and the small size of
Ala2 likely contributes to homogeneous demethioninylation
in E. coli. Residues 16 and 17 are Leu and Phe, so the 4–17Journal of Lipids 7
deletion results in removal of basically all of the N-terminal
hydrophobic residues.
Our second hypothesis was that increasing the polar
character of the putative HDL binding site, which is deﬁned
by a large number of surface hydrophobic residues, would
increase the solubility of the protein. We speculated that
this might not aﬀect the structure or activity of the protein
signiﬁcantly since it is on the surface and pointed away from
the active site. Residues proposed to be involved in HDL
anchoring lie principally in Helix 2 and the adjacent loops,
as well as Helix 1 [16] (Figure 3). We modiﬁed this surface
based on inspection of the crystal structure of G2E6 with
a limited library of polar amino acids (Glu, Gln, and Lys)
to yield ΔHDL-huPON1 (Y24E Y185E F186Q L187K Y190K
L191Q W194K L198E L200Q W202K M289Q F293E).
Our third hypothesis was that only a subset of the surface
changes in the directed evolution of G2E6 was responsible
for increasing the solubility of the protein. In particular, we
speculated that sites that became signiﬁcantly more polar
(either nonpolar to polar or charged, or polar to charged)
would contribute to most of the solubility increase seen
with G2E6 [17]. We chose 15 sites where residues became
signiﬁcantly more polar from huPON1 to G2E6 (I5T N19R
Q21K L31H N78D N80D S81K P82S L98S G101E A137S
Q192K Y197H N265D N309D). We then examined whether
any of the mutations were in the vicinity of any of the other
44 mutations present in G2E6, and we found a single case
wherein Lys192 made a hydrogen bond to Ser166. Position
192 is an interesting site because it is a site of human
polymorphism, where Gln and Arg are common [32]. Also,
of all 59 mutations in G2E6, only ﬁve positions are within
9 ˚ A of the active-site His115 residue, and of those only the
side chains of Ser166 and Lys192 point toward the active site.
Consequently, with the idea that coupling between these two
positions could be important, we also included the N166S
mutation to yield g2e6p-huPON1.
We also engineered several combinations of these vari-
ants, by combining the N-terminal deletion to ΔHDL-
huPON1 (to yield ΔN-ΔHDL-huPON1) and the g2e6p-
huPON1 (to yield ΔN-g2e6p-huPON1), to examine the
potential for additivity in increasing solubility.
3.2. GFP-Fusion Screen for Solubility. To assess the solubility
of these engineered variants, we turned to the GFP-fusion
screen developed by Waldo and colleagues [24]. In this
screen, a protein of interest is fused to the N-terminus of
“folding reporter” GFP, and cellular ﬂuorescence develops
in proportion to the solubility of the POI. In reality, the
cellular ﬂuorescence is related to the amount of soluble
protein, but in this case all of the tested variants of PON1
expressed in similar signiﬁcant quantities in whole-cell lysate
(not shown), so we can assume that increased ﬂuorescence is
due to increased partitioning into the soluble fraction. We
constructed frGFP by combining EGFP (F64L S65T) [27]
with Stemmer’s “cycle 3” GFPuv (F99S M153T V163A) [26],
and we generated our own fusion construct in a pET11a
plasmid. We also tested the screen by assaying unfused frGFP
as well as fusions of T4 lysozyme, yeast triosephosphate
isomerase(TIM),G2E6PON1,andhumanPON1.Cellswith
the T4 lysozyme fusion were more ﬂuorescent than those
with the unfused GFP; yeast TIM resulted in comparable ﬂu-
orescence, G2E6 with lower ﬂuorescence, and huPON1 with
even lower ﬂuorescence than G2E6 (data not shown). Cells
were washed with phosphate-buﬀered saline and normalized
for cell density before ﬂuorescence was measured.
The solubility results are shown in Figure 4.A sw e
observed in our controls, the ﬂuorescence was about 4.5-fold
greater for G2E6 than huPON1. The three engineered vari-
ants were all more soluble than huPON1: the ﬂuorescence
for ΔN-huPON1 was about twice that of huPON1, g2e6p-
huPON1 was about four times as ﬂuorescent, and ΔHDL-
huPON1 was about six times as ﬂuorescent. Interestingly,
g2e6p-huPON1 had nearly the same ﬂuorescence level as
G2E6, consistent with our hypothesis that the increased
solubility of G2E6 was essentially entirely due to the subset
of residues that became more polar on the surface of PON1.
Mutation of the hydrophobic residues in the putative HDL
binding site to polar and charged residues (ΔHDL-huPON1)
had the greatest eﬀect on the protein solubility, exceeding
that of G2E6 by almost 50%.
The removal of the hydrophobic N-terminal leader had
the least eﬀect of the three solubilizing concepts (∼2.4-
fold). However, the eﬀects of the N-terminal deletion were
mostlyadditivewiththeΔHDLandg2e6pmutationsets.The
ﬂuorescence increased an additional 2-fold for ΔN-g2e6p-
huPON1 over g2e6p-huPON1 and an additional ∼1.8-fold
for ΔN-ΔHDL-huPON1 over ΔHDL-huPON1.
3.3. Expression and Puriﬁcation of Engineered Variants. We
wishedtopurifythehuPON1solubilizedvariantstomeasure
their activity and stability, as well as to verify their soluble
expression. However, we found that the frGFP fusions were
expressed at such low levels that it was inconvenient to work
with them. As a result, we recloned the constructs, fusing
a hexahistidine tag and maltose-binding protein to the N-
terminus of the huPON1 variants. When these variants were
puriﬁed by NiNTA aﬃnity chromatography, they appeared
to copurify with a signiﬁcant number of smaller proteins at
reduced but signiﬁcant levels (Figure 5). Note that, for the
MBP fusions, the amount of soluble protein captured in the
puriﬁcation was greatest for ΔN-ΔHDL-huPON1 and then
ΔHDL-huPON1; g2e6p-huPON1 and ΔN-huPON1 were
puriﬁed in comparable lower amounts, consistent with the
screening data. It proved diﬃcult to purify the proteins with
increasinglystringentwashes,whichmadeussuspectthatthe
other bands on the SDS-PAGE gel were truncation products
of the full-length constructs. A blot with the anti-His6
reagent HisProbe-HRP conﬁrmed that the smaller proteins
contained a hexahistidine tag.
These truncation products likely arose from proteolysis
due to poor protein stability or ineﬃcient folding of the
huPON1variants. We speculatedthat moving the 6×His tag
to the C-terminus might allow us to capture the full-length
proteins. Consequently, we recloned selected constructs into
a pET11a vector as fusions with MBP on the N-terminus
and a hexahistidine tag on the C-terminus. However, the
yields of these full-length proteins were low. We previously
observed a similar result with huPON1 and found that8 Journal of Lipids
coexpression with DnaK/DnaJ/GrpE chaperones as well as
expressionatlowertemperaturesenhancedtheproductionof
full-length protein (V. Shete, B. Competty, TJM, manuscript
in preparation). When the MBP-PON1-His6 constructs were
expressed in E. coli overexpressing the DnaK chaperone
system, full-length huPON1 variants could be puriﬁed at
higher yields with no signiﬁcant evidence of truncation
(Figure 5). A protein the same size as DnaJ was found
to copurify with the MBP fusions. We veriﬁed that no
signiﬁcant hydrolytic activity above background could be
observed from the lysates of cells overexpressing the DnaK
chaperones.
Because G2E6 can be puriﬁed as a thioredoxin or MBP
fusion (not shown) with no evidence of these truncation
products, it is likely that all of the huPON1 derivatives fold
less well than G2E6.
3.4.ActivityandStabilityofEngineeredVariants. The activity
of our engineered PON1 variants against phenyl acetate and
the OP compounds paraoxon and EMP was determined
and compared with huPON1 and G2E6 (see Figure 6 for
structures of the substrates). Because the activity levels were
modest and initial trials suggested that the Km values were
likelytobenearthetopoftheconcentrationrangethatcould
be tested with each substrate, speciﬁc activities are reported
f o rs o m es u b s t r a t e s( T a b l e1).
Assuming that 3.3mM phenyl acetate nearly saturates
our PON1 variants, we can calculate a comparable speciﬁc
activity for huPON1 based on the kcat v a l u ew er e p o r t e d
previously [5]. The huPON1 used in that study was not
an MBP fusion, but if we calculate the speciﬁc activity
using the mass of the fusion for comparison, we arrive at a
speciﬁc activity of 690μmolmin−1 mg−1. The corresponding
value for G2E6 is 820μmolmin−1 mg−1. When we expressed
huPON1 as an MBP fusion exactly as we did for the huPON1
variants here, the speciﬁc activity was 4-fold lower than that
reported previously for enzyme puriﬁed from 293T cells.
All of the variants engineered here had considerably lower
activity. The ΔN-huPON1 and g2e6p-huPON1 were about
10-fold lower in activity than huPON1. The ΔHDL-huPON1
variant was about another 20-fold lower than the other
two variants. Moreover, the N-terminal deletion reduced the
activity of g2e6p-huPON1 by 5-fold, and it approximately
halvedthealready-lowactivityoftheΔHDL-huPON1.While
all three of these methods of solubilization did in fact
produce more soluble material, the protein produced had
lower speciﬁc activity, with the most signiﬁcant reduction in
activity for the ΔHDL-huPON1.
The activity of huPON1 against paraoxon is considerably
lower than against phenyl acetate (the corresponding speciﬁc
activity is 0.3μmolmin−1 mg−1), so it is not surprising that
we were only able to detect activity against paraoxon with
a single variant, the g2e6p-huPON1. The g3e6p-huPON1
activity was about 30-fold below the calculated speciﬁc
activity for huPON1 expressed in 293T cells, on par with the
corresponding reduction in phenyl acetate activity. However,
when huPON1 was expressed the same way, the activity
against paraoxon was actually 35-fold lower than g2e6p-
huPON1 and about 100-fold lower than the 293T-expressed
material. The reason for this reduction against paraoxon is
not clear. Using EMP, which is an excellent OP substrate for
PON1, we also observed that g2e6p-huPON1 was the most
activevariant,anditwasabout2.5-foldmoreactivethanΔN-
huPON1and100-foldmoreactivethanΔN-g2e6p-huPON1.
We could not detect activity against EMP with ΔHDL-
huPON1. The activity of g2e6p-huPON1 was also slightly
higher than huPON1 with EMP (∼1.5-fold), although much
less so than with paraoxon.
We were also interested in the eﬀects of each of these sol-
ubilizing sets of mutations on the stabilities of the resulting
proteins.BecausePON1denaturesirreversiblyuponheating,
thermalinactivationisagoodmeasureoftherelativestability
of the variants [33]. With phenyl acetate activity as the read-
out, the T1/2 for huPON1 was roughly 55–60◦C (Figure 7).
The ΔN-huPON1 was increased slightly in stability, to about
60◦C. Both g2e6p-huPON1 and ΔN-g2e6p-huPON1 have
T1/2 valuescloseto55◦C,andboth ΔHDL-huPON1andΔN-
ΔHDL-huPON1 have T1/2 values close to 40◦C. A similar
experiment using EMP as the substrate produced similar
results,withhuPON1showingamidpointintheinactivation
curve around 55◦Ca n dΔN-huPON1 and g2e6p-huPON
around 50◦C. Overall we conclude that the N-terminal
deletion had little eﬀect on the stability, the g2e6p mutations
reduced the stability of huPON1 slightly, and the ΔHDL
mutations reduced it signiﬁcantly.
3.5. Humanization of 4E9. We wished to test whether we
couldproduceasolubilizedhuPON1withsigniﬁcantactivity
toward an OP compound, eﬀectively “humanizing” an
engineered PON1. The g2e6p-huPON1 variant appeared
to aﬀord the best combination of solubility, activity, and
stability from among our original variants, so we elected
to use those mutations to humanize an engineered PON1.
Gupta and colleagues recently reported the engineering of a
PON1 variant called 4E9 that has signiﬁcant activity toward
the cyclosarin (GF) analog CMP and notably increased
activity against the more toxic SP enantiomorph of CMP
[15]. It also has signiﬁcant activity against authentic GF, as
determined from an AChE inactivation assay in which GF
is generated in situ at low concentrations. 4E9 is derived
from G3C9, with the mutations L69G S111T H115W H134R
F222S T332S, all of which are in the presumed active site
except for S111T. Therefore, we generated a variant of
huPON1 with surface solubilizing mutations derived from
G2E6 (akin to the g2e6p-huPON1 described above and in
Figure 1) and the 4E9 mutations obtained during directed
evolution. The resulting variant, hum-4E9 (Figure 8), has
two additional nonpolar-to-polar mutations that we did not
elect to make in the g2e6p-huPON1: A126T and V206T. As
anadditionaltestofthesolubilizationaﬀordedbythesurface
polar mutations, we not only expressed hum-4E9 as an MBP
fusion with C-terminal 6×his tag, but we also produced it
with no fusion partner (with a C-terminal 6×His tag only,
which is also present in G3C9 and 4E9). The MBP fusion
of hum-4E9 was puriﬁed in similar yield to the other MBP
fusions of the huPON1 variants and G2E6. The unfused
hum-4E9 was produced in about 5-fold lower yield than this
and approximately 25-fold lower yield than 4E9 itself.Journal of Lipids 9
Table 1: Aryl esterase and OPase activity of huPON1 variants. Phenyl acetate and paraoxon speciﬁc activities were determined at 3.3mM
and 2.6mM substrate, respectively. Errors for the speciﬁc activities are the standard errors from 3 trials. EMP values were determined at
constant 2% methanol, and the errors are with respect to the ﬁt. n.d.:n o td e t e c t e d .— :kcat/Km is reported from a linear ﬁt of initial rate
versus substrate concentration when the enzyme could not be saturated under experimental conditions.
Variant Phenyl acetate Paraoxon EMP
speciﬁc activity
μmolmin−1 mg−1
speciﬁc activity
μmolmin−1 mg−1 kcat s−1 Km mM kcat/Km
M−1 s−1
huPON1 160 ±20 0.003 ±0.001 0.027 ±0.001 0.14 ±0.01 190 ±20
ΔN- 17 ±9 n.d. — — 117 ±8
g2e6p- 20 ±50 .011 ±0.002 0.041 ±0.003 0.14 ±0.02 300 ±50
ΔN-g2e6p- 4 ±1 n.d. —— 2 .2 ±0.1
ΔHDL- 1.2 ±0.2 n.d. n.d.
ΔN-ΔHDL- 0.8 ±0.2 n.d. n.d.
Table 2: Activity of hum-4E9. kcat/Km values were determined under constant 2% methanol conditions for all three substrates. None of the
enzymescouldbesaturatedwiththosesubstratesunderexperimentalconditions.SP-CMPspeciﬁcactivitiesweredeterminedat∼0.0125mM
SP-CMP. GF kapp hydrolysis rate constants and stereoisomeric preferences were determined using GF at 0.315mM. ND: not determined.
paraoxon EMP CMP SP-CMP GF
Variant kcat/Km
M−1 s−1
kcat/Km
M−1 s−1
kcat/Km
M−1 s−1
speciﬁc activity
nmol min−1 mg−1
kapp
M−1 s−1 RP :SP ratio
4E9 3,100 ±200 24,000 ±1,000 17,000 ±3,000 1.1 ±0.1N DN D
hum-4E9 750 ±20 7,500 ±600 3,200 ±300 1.10 ±0.05 8,700 3.5:1
MBP-hum-4E9 230 ±80 6,800 ±300 6,000 ±2000 ND 5,400 6:1
3.6. Characterization of Hum-4E9. Not only was hum-4E9
expressed in signiﬁcant quantities both with and with-
out an MBP fusion tag, but the enzyme was also very
active (Table 2). The kcat/Km for hydrolysis of EMP was
6,800M−1 s−1 for the MBP fusion protein and surprisingly
was slightly higher (7,500M−1 s−1) for the protein produced
without the fusion partner. This represents more than a 20-
fold increase over g2e6p-huPON1. We have observed that
the activity of G3C9 and 4E9 against EMP is similar (within
2-fold, CKH and TJM, unpublished), suggesting that the
i n c r e a s ei nE M Pa c t i v i t yb e t w e e ng 2 e 6 p - h u P O N 1a n dh u m -
4E9cannotbeattributedentirelytotheactive-sitemutations.
The rates of hydrolysis of CMP were also high. For
this substrate, the MBP fusion protein had slightly higher
activity than the untagged version (6,000M−1 s−1 versus
3,200M−1 s−1). The value for the MBP fusion is within 3-
fold of the CMP activity of 4E9 measured under identical
conditions. There is also signiﬁcant activity against authentic
GF (∼6,000M−1 s−1). Tawﬁk reports that G3C9 has no
detectableactivityagainsttheSP isomerofCMP,andwehave
also observed this (CKH and TJM, unpublished). In the RP-
CMP depletion assay, we found that 4E9 and hum-4E9 had
the same level of activity against SP-CMP, despite the overall
lower level of activity for hum-4E9 against CMP. The ratio of
the rate constants for hydrolysis of the RP :SP isomers of GF
was about 4:1, suggesting that hum-4E9 displays substantial
activity against the more toxic isomer of GF, even though it
is still selective for the less toxic isomer.
We also examined the stability of hum-4E9 by thermal
inactivation, using EMP as a substrate (Figure 8). The
apparent T1/2 values were ∼50◦C for both the MBP fusion
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and the unfused protein. This level of stability is consistent
with that of g2e6p-huPON1.
4. Discussion
There is relatively little known about the eﬀects of mutations
on protein solubility or about how to engineer proteins10 Journal of Lipids
1 234 150
102
76
52
38
31
 
(
k
D
)
(a)
123456
(b)
1 23456
(c)
Figure 5:PuriﬁcationofhuPON1variantsfromE.coli.(a)SDS-PAGEofpuriﬁcationfromHis6-MBP-PON1fusionsfromthepHMTplasmid
using NiNTA chromatography. (1) ΔN-huPON1; (2) ΔHDL-huPON1; (3) ΔN-ΔHDL-huPON1; (4) g2e6p-huPON1. (b) Blot of SDS-PAGE
of PON1 variants as His6-MBP-PON1 fusions with HisProbe-HRP (Pierce), demonstrating that many of the smaller proteins bear the
6×His tag and are likely proteolytic fragments. (1) ΔHDL-huPON1 lysate; (2) and (3), puriﬁed ΔHDL-huPON1; (4) cleaved MBP; (5)
puriﬁed g2e6p-huPON1; (6) puriﬁed ΔN-huPON1. (c) SDS-PAGE of puriﬁed proteins from the MBP-PON1-His6 constructs in pET11a
with coexpression of DnaK/DnaJ/GrpE from pKJE7 (Takara Bioscience). (1) huPON1; (2) ΔN-huPON1; (3) ΔHDL-huPON1; (4) ΔN-
ΔHDL-huPON1; (5) g2e6p-huPON1; (6) ΔN-g2e6p-huPON1.
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for increased solubility. This is one reason that Waldo and
colleagues invented their GFP-fusion screen, so that directed
evolution from random mutagenesis could be used to select
formoresolubleproteins[24].Itseemsintuitivelyreasonable
that increasing the fraction of polar and charged residues on
the surface of a protein would increase solubility, but natural
proteinsgenerallyhavethesamefractionofpolarresidueson
theirsurfacesastheydoinoverallcomposition,meaningthat
about half of surface residues are hydrophobic. Mutations
to the surfaces of proteins are often naively thought of as
neutral, but solubilizing mutations also aﬀect the solubility
of the unfolded state. Consequently, they can aﬀect both the
stability and folding of proteins. Proteins from thermophiles
diﬀer more from their mesophilic counterparts on their
surfaces than in factors such as hydrophobic core packing
[34].
Here we explored the eﬀects of three diﬀerent kinds
of mutations to PON1, to assess their impact on solu-
bility, activity, and stability. Two of the approaches were
rational—weremovedthehydrophobicsignalsequencefrom
the N-terminus of the proteins, and we solubilized the
putative HDL binding site by replacing a large number of
closely grouped surface hydrophobic residues with polar and
charged amino acids. The third approach was based on the
directed evolution of G2E6. We postulated that most of
the increased solubility of G2E6 over huPON1 arose from
substitution of residues on the surface to more polar amino
acids. We constructed the ΔHDL and g2e6p mutants of
huPON1, as well as the ΔN mutants of huPON1 and the
othertwovariants.Weexaminedthesolubilityofthevariants
using GFP-fusion screening. These fusions were produced at
low levels, so we recloned the variants as MBP fusions for
higher yield expression and in vitro characterization.
All three of the sets of mutations increased the solubility
relative to huPON1, but to diﬀerent degrees. The deletion
of the N-terminal signal sequences had the least eﬀect and
aﬀorded roughly the same amount of solubilization to the
other variants as it did to huPON1. These results suggest that
the eﬀects of the diﬀerent sets of solubilizing mutations can
be at least partially additive. The N-terminal deletion also
resulted in only a modest decrease in the activity and little
change in the stability of huPON1. It is interesting that there
is any decrease in activity for this variant (ΔN-huPON1),
sincetheN-terminusisdisorderedinthecrystalandnotnear
the active site of the protein. The ΔHDL mutant aﬀorded
the greatest solubilization, but at the highest cost to both
activity and stability. While these mutations were a much
more radical change to the protein than the N-terminal
deletion, it is still somewhat surprising that they have such
a profound impact on the activity of the protein. It is known
that the activity of PON1, particularly lactonase activity, is
stimulatedbybindingtoHDL[20].WhilethereisnoHDLin
these preps, either remnants of bacterial cellular lipids (such
as lipopolysaccharide) or detergent added to the puriﬁcation
maypartiallysubstituteforHDL.Itispossiblethatbindingto
lipidhaseitheradirecteﬀectonthestructureoftheactivesite
or that it aﬀects other properties such as enzyme dynamics
that cannot be easily recapitulated in mutants that do not
bind lipid.
Perhaps the single most important result of this work
is the demonstration that the subset of surface mutations
that become more polar in G2E6 entirely account for
the increased solubility of G2E6 over huPON1. This is
potentially a useful approach for minimizing the number of
mutations that arise from random mutagenesis and directedJournal of Lipids 11
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Figure 7: Stability of huPON1 variants. The residual activities against phenyl acetate after 10min of incubation at the indicated temperatures
are shown. The residual activity after incubation at 20◦C was taken as 100%. (a) huPON1 and ΔN-huPON1; (b) ΔHDL-huPON1 and
ΔN-ΔHDL-huPON1; (c) g2e6p-huPON1 and ΔN-g2e6p-huPON1.
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Figure 8: Humanization of 4E9. (a) The g2e6p mutations are shown in green spheres; the three additional mutations M55L, A126T, and
V206T, are shown in blue spheres; the 4E9 mutations (with respect to G3C9) are shown in red spheres. (b) Thermal inactivation of hum-4E9
produced with and without MBP fusion is compared to huPON1 and 4E9. Residual activity here was from EMP hydrolysis rather than
phenyl acetate because the H115W mutation renders PON1 inactive against phenyl acetate.
evolution of other proteins. The g2e6p-huPON1 variant was
only slightly destabilized relative to huPON1, and it was
reduced in activity by only a small amount. Mutations from
huPON1 to G2E6 mostly arose from residues that are found
in other mammalian paraoxonases, which likely aided in
making them minimally detrimental to the structure and
function. Still, we can conclude that some of the other 43
mutations from huPON1 to G2E6 must be important for
other parameters, such as the higher activity of G2E6 relative
to g2e6p-huPON1.
For huPON1 and all of the soluble variants, we observed
thatconsiderableamountsofproteolyticproductswerepuri-
ﬁed and that these could be eliminated by coexpression of
the DnaK chaperone system. Such products are not observed
with thioredoxin or MBP fusions of G2E6, which suggests
that one of the major eﬀects of the directed evolution to
G2E6 was an increase in the folding rate of the protein. Since
themutationsthatsolubilizedtheg2e6p-huPON1werealone
not suﬃcient to eliminate these products, we can conclude
that this eﬀect also arises from some of the other 43 residues
that change from huPON1 to G2E6. It will be interesting to
determine which mutations are responsible for this eﬀect.
Overall, our results emphasize that surface mutations, aside
from having solubility eﬀects, are often far from neutral on
the stability and folding of proteins.
The idea of “humanization” of engineered proteins was
conceived in the development of antibody drugs, where it is
necessary to raise antibodies in mice or other animals, but a
consequence of which is immune response to the constant
regions of the heterologous antibodies. It is often possible
to engineer molecules with human antibody surfaces but
aﬃnity matured binding sites, albeit sometimes with loss
of aﬃnity or stability [25]. There are not yet suﬃcient
data to know if mammalian chimeric PON1 variants like12 Journal of Lipids
G3C9 and its progeny will elicit immune responses, but
it is a concern given the degree of sequence divergence.
Using an approach reminiscent of antibody humanization,
we implanted the active site of the engineered 4E9 variant
intohuPON1andsolubilizedhuPON1withthesurfacepolar
mutations from G2E6. We have shown the activity and the
eﬀects of mutations in the huPON1 and G2E6 backgrounds
to be highly divergent, so it was not clear that introduction
of the 4E9 active-site mutations would aﬀord high CMP and
GF activity as observed for 4E9. Interestingly, the engineered
variant does exhibit 4E9-like activity, including similar stere-
ochemical preferences for CMP and GF. Our hum-4E9 still
diﬀers in a signiﬁcant number of positions from huPON1
and expresses at lower levels than 4E9, so further engineering
may be required to aﬀord an ideal molecule. Nonetheless,
the current data present a promising proof of principle that
protein solubility can be altered in a controlled and rational
way.
Finally, it is of note that two of the mechanisms that
we chose to solubilize huPON1 (ΔNa n dΔHDL) are
likely to reduce or exclude HDL binding, while the g2e6p
mechanism is likely to be compatible with it. These mutants,
and perhaps related mutants in G3C9, may be useful for
examining the role of HDL binding in the function and
regulation of PON1. For example, we have found that
mutation of a single Trp in the putative HDL binding site
of G3C9 dramatically increases the solubility of G3C9 and
consequently may reduce its binding to HDL (R. Baldauﬀ
and TJM, unpublished). It is unclear what eﬀect untethering
PON1 from HDL will have on its physiological function, its
serum lifetime, or its recognition by the immune system, but
it may help solve the puzzle of exactly what PON1 is doing
in vivo.
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